Product Profile - Overview

NECT
NECT = Nifurtimox-Eflornithine Combination Therapy
NECT is the first new, improved treatment option in 25 years for stage 2 (advanced stage) human African trypanosomiasis (HAT) also known as sleeping sickness. It consists of a simplified coadministration of nifurtimox, which is given orally, and eflornithine, which is given intravenously. Launched in 2009 Included  in the Essential Medicines List (EML) of the WHO since 2009 Much safer than Melarsoprol, a highly toxic, arsenic-based drug that kills 5% of treated patients, still used in 50% of patients. Compared to eflornithine monotherapy, the best previously available treatment for stage 2 HAT, NECT is: As effective Safer Easier to administer More cost-effective Requests shorter hospitalisation The result of a six-year partnership between NGOs, governments, pharmaceutical companies, and the WHO. Donated by Sanofi and Bayer Schering Pharma AG Available in 12 African countries that account for 99% of reported HAT cases More than 6'000 treatments distributed Download NECT dossier in English [PDF 350KB] Téléchargez le dossier NECT en français [PDF 317KB] Read more about NECT project		NECT News
		Implementation progress Available in 12 African countries Request supply signed by Congo and Guinea
		Recent Scientific PublicationsPLos NTD, May 2009 NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness
		Recent Events